SCCHN clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab or bevacizumab to subjects with advanced solid tumors.
Los Angeles, California and other locations